NEW YORK (GenomeWeb News) – Cernostics and Geisinger Health Systems today announced a partnership to develop diagnostics for detecting cellular and molecular differences in patient tissue samples.
The partnership will focus on developing cancer diagnostics that may lead to better prediction of disease progression, and the identification of patients who may benefit from specific cancer treatments, Geisinger said in a statement. The technologies to be developed may also have the potential to lower costs, increase quality, assess the safety of current cancer treatments, and spur the creation of new treatments, the Danville, Pa.-based health system added.
Terms of the deal were not disclosed.
Cernostics' expertise in digital pathology and advanced tissue-based diagnostics will be combined with Geisinger's MyCode biorepository and tumor bank, which is linked to the health system's electronic health records.
As part of the agreement, Cernostics completed a Series A financing round, led by Novitas Capital, Geisinger, and the Pittsburgh Life Science Greenhouse. Cernostics told GenomeWeb Daily News that it raised a total of $2.6 million in the round.
The funds from Novitas and Pittsburgh Life will be used to support development of the technologies and integration of information stemming from the technologies into a "digital workflow of pathology" and electronic health records, said Michel Nederlof, president and chief technology officer of Cernostics.
Cernostics, based in Pittsburgh, was spun out of Cellumen in 2008 to concentrate on personalized medicine. Its primary method, called TissueCipher Pathology, integrates digital imaging pathology, highly multiplexed panels of fluorescence biomarkers, informatics, and EMR systems, according to the company.